Healthcare resource utilization and costs associated with renal, bone and cardiovascular comorbidities among persons living with HIV compared to the general population in Quebec, Canada.

Autor: Baribeau V; PeriPharm Inc, Montreal, Quebec, Canada., Kim CJ; Gilead Sciences Canada, Inc, Mississauga, Ontario, Canada., Lorgeoux RP; Gilead Sciences Canada, Inc, Mississauga, Ontario, Canada., Brisebois J; Gilead Sciences Canada, Inc, Mississauga, Ontario, Canada., Tossonian H; Gilead Sciences Canada, Inc, Mississauga, Ontario, Canada., Lachaine J; PeriPharm Inc, Montreal, Quebec, Canada.; Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Jul 11; Vol. 17 (7), pp. e0262645. Date of Electronic Publication: 2022 Jul 11 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0262645
Abstrakt: There is limited understanding on healthcare utilization and costs of age-related comorbidities such as cardiovascular, bone and renal disease/disorder in people living with human immunodeficiency virus, so we compared comorbidity prevalence and associated healthcare utilization and costs. Through the Quebec health insurance database, people living with human immunodeficiency virus on antiretroviral therapy for ≥6 months from January 2006 to June 2012 were categorized by their comorbidity status using International Classification of Diseases (ICD)-9 codes, and controls without human immunodeficiency virus diagnosis or antiretroviral therapy use were age and gender matched. We compared healthcare utilization and costs. A total of 3,905 people living with human immunodeficiency virus and 11,715 control individuals were included. The mean age of people living with human immunodeficiency virus was 45.3 years and 77.3% were men. Prevalence of comorbidities was higher and occurred earlier in people living with human immunodeficiency virus and increased with older age regardless of human immunodeficiency virus status. Interestingly, bone comorbidity was high (37%) and 5-fold greater in people living with human immunodeficiency virus <20 years than the controls. Polypharmacy and comorbidity scores were greater in people living with human immunodeficiency virus than controls (p<0.01), as were cardiovascular, bone and renal comorbidities (40.3%, 26.0% and 5.5%, respectively; p<0.01). People living with human immunodeficiency virus had higher healthcare utilization and costs than controls largely due to longer hospital stays and prescriptions. Mean total healthcare cost/person/year for people living with human immunodeficiency virus was CAD$6,248 and was highest for those with renal disease (CAD$19,617). Comorbidities in people living with human immunodeficiency virus are more prevalent, occur earlier and incur a higher burden on the healthcare system; earlier screening and improved preventative and management strategies may reduce the burden to people living with human immunodeficiency virus and to the healthcare system.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Connie J. Kim, René-Pierre Lorgeoux, Josée Brisebois, and Harout Tossonian are employees of Gilead Sciences Canada Inc.; Jean Lachaine has received research funds from Gilead Sciences Canada Inc. to conduct this study; Véronique Baribeau has nothing to declare.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje